These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 34407339)

  • 21. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
    Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
    Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial.
    Gharbharan A; Jordans C; Zwaginga L; Papageorgiou G; van Geloven N; van Wijngaarden P; den Hollander J; Karim F; van Leeuwen-Segarceanu E; Soetekouw R; Lammers J; Postma D; Kampschreur L; Groeneveld G; Swaneveld F; van der Schoot CE; Götz H; Haagmans B; Koopmans M; Bogers S; Geurtsvankessel C; Zwaginga JJ; Rokx C; Rijnders B;
    Clin Microbiol Infect; 2023 Feb; 29(2):208-214. PubMed ID: 36007870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
    Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
    Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
    O'Donnell MR; Grinsztejn B; Cummings MJ; Justman JE; Lamb MR; Eckhardt CM; Philip NM; Cheung YK; Gupta V; João E; Pilotto JH; Diniz MP; Cardoso SW; Abrams D; Rajagopalan KN; Borden SE; Wolf A; Sidi LC; Vizzoni A; Veloso VG; Bitan ZC; Scotto DE; Meyer BJ; Jacobson SD; Kantor A; Mishra N; Chauhan LV; Stone EF; Dei Zotti F; La Carpia F; Hudson KE; Ferrara SA; Schwartz J; Stotler BA; Lin WW; Wontakal SN; Shaz B; Briese T; Hod EA; Spitalnik SL; Eisenberger A; Lipkin WI
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33974559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.
    Salazar E; Christensen PA; Graviss EA; Nguyen DT; Castillo B; Chen J; Lopez BV; Eagar TN; Yi X; Zhao P; Rogers J; Shehabeldin A; Joseph D; Masud F; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Musser JM
    Am J Pathol; 2021 Jan; 191(1):90-107. PubMed ID: 33157066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
    Sturek JM; Thomas TA; Gorham JD; Sheppard CA; Raymond AH; Petros De Guex K; Harrington WB; Barros AJ; Madden GR; Alkabab YM; Lu DY; Liu Q; Poulter MD; Mathers AJ; Thakur A; Schalk DL; Kubicka EM; Lum LG; Heysell SK
    Microbiol Spectr; 2022 Feb; 10(1):e0256021. PubMed ID: 35196802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
    Ortigoza MB; Yoon H; Goldfeld KS; Troxel AB; Daily JP; Wu Y; Li Y; Wu D; Cobb GF; Baptiste G; O'Keeffe M; Corpuz MO; Ostrosky-Zeichner L; Amin A; Zacharioudakis IM; Jayaweera DT; Wu Y; Philley JV; Devine MS; Desruisseaux MS; Santin AD; Anjan S; Mathew R; Patel B; Nigo M; Upadhyay R; Kupferman T; Dentino AN; Nanchal R; Merlo CA; Hager DN; Chandran K; Lai JR; Rivera J; Bikash CR; Lasso G; Hilbert TP; Paroder M; Asencio AA; Liu M; Petkova E; Bragat A; Shaker R; McPherson DD; Sacco RL; Keller MJ; Grudzen CR; Hochman JS; Pirofski LA; ; Parameswaran L; Corcoran AT; Rohatgi A; Wronska MW; Wu X; Srinivasan R; Deng FM; Filardo TD; Pendse J; Blaser SB; Whyte O; Gallagher JM; Thomas OE; Ramos D; Sturm-Reganato CL; Fong CC; Daus IM; Payoen AG; Chiofolo JT; Friedman MT; Wu DW; Jacobson JL; Schneider JG; Sarwar UN; Wang HE; Huebinger RM; Dronavalli G; Bai Y; Grimes CZ; Eldin KW; Umana VE; Martin JG; Heath TR; Bello FO; Ransford DL; Laurent-Rolle M; Shenoi SV; Akide-Ndunge OB; Thapa B; Peterson JL; Knauf K; Patel SU; Cheney LL; Tormey CA; Hendrickson JE
    JAMA Intern Med; 2022 Feb; 182(2):115-126. PubMed ID: 34901997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Outpatient Treatment for Covid-19 with Convalescent Plasma.
    Sullivan DJ; Gebo KA; Shoham S; Bloch EM; Lau B; Shenoy AG; Mosnaim GS; Gniadek TJ; Fukuta Y; Patel B; Heath SL; Levine AC; Meisenberg BR; Spivak ES; Anjan S; Huaman MA; Blair JE; Currier JS; Paxton JH; Gerber JM; Petrini JR; Broderick PB; Rausch W; Cordisco ME; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Raval JS; Kassaye SG; Foster EC; Roth M; Marshall CE; Yarava A; Lane K; McBee NA; Gawad AL; Karlen N; Singh A; Ford DE; Jabs DA; Appel LJ; Shade DM; Ehrhardt S; Baksh SN; Laeyendecker O; Pekosz A; Klein SL; Casadevall A; Tobian AAR; Hanley DF
    N Engl J Med; 2022 May; 386(18):1700-1711. PubMed ID: 35353960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
    Park HS; Yin A; Barranta C; Lee JS; Caputo CA; Sachithanandham J; Li M; Yoon S; Sitaras I; Jedlicka A; Eby Y; Ram M; Fernandez RE; Baker OR; Shenoy AG; Mosnaim GS; Fukuta Y; Patel B; Heath SL; Levine AC; Meisenberg BR; Spivak ES; Anjan S; Huaman MA; Blair JE; Currier JS; Paxton JH; Gerber JM; Petrini JR; Broderick PB; Rausch W; Cordisco ME; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Raval JS; Kassaye SG; Marshall CE; Yarava A; Lane K; McBee NA; Gawad AL; Karlen N; Singh A; Ford DE; Jabs DA; Appel LJ; Shade DM; Lau B; Ehrhardt S; Baksh SN; Shapiro JR; Ou J; Na YB; Knoll MD; Ornelas-Gatdula E; Arroyo-Curras N; Gniadek TJ; Caturegli P; Wu J; Ndahiro N; Betenbaugh MJ; Ziman A; Hanley DF; Casadevall A; Shoham S; Bloch EM; Gebo KA; Tobian AA; Laeyendecker O; Pekosz A; Klein SL; Sullivan DJ
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
    Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
    Agarwal A; Mukherjee A; Kumar G; Chatterjee P; Bhatnagar T; Malhotra P;
    BMJ; 2020 Oct; 371():m3939. PubMed ID: 33093056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
    Gordon O; Brosnan MK; Yoon S; Jung D; Littlefield K; Ganesan A; Caputo CA; Li M; Morgenlander WR; Henson SN; Ordonez AA; De Jesus P; Tucker EW; Peart Akindele N; Ma Z; Wilson J; Ruiz-Bedoya CA; Younger MEM; Bloch EM; Shoham S; Sullivan D; Tobian AA; Cooke KR; Larman B; Gobburu JV; Casadevall A; Pekosz A; Lederman HM; Klein SL; Jain SK
    JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34855624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
    Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
    Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
    Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ;
    mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.